Jupiter Endovascular’s Pulmonary Embolectomy System Hits Primary Endpoints in Trial

Jupiter Endovascular’s pulmonary embolectomy system hits primary endpoints in trial

Jupiter’s Vertex uses transforming fixation, a technology designed to improve catheter navigation through the right heart into the pulmonary arteries.The post Jupiter Endovascular’s pulmonary embolectomy system hits primary endpoints in trial appeared first on Medical Device Network.

EuroPCR 2026: Jupiter Endovascular announces positive results from SPIRARE II pivotal trial

Vertex PE system Jupiter Endovascular has announced that the SPIRARE II pivotal trial evaluating the use of the company’s Vertex pulmonary embolectomy system in patients with acute, intermediate-risk pulmonary embolism (PE) met both of its primary endpoints, demonstrating meaningful heart recovery and clinical safety. Late-breaking data from the trial were presented by Catalin Toma, director of interventional cardiology at the UPMC Heart and Vas…

Jupiter Endovascular Reports Positive Results from SPIRARE II Pivotal Trial

“SPIRARE II was designed not only to support regulatory clearance, but also to generate a robust clinical dataset that includes paired invasive hemodynamics and detailed patient-level data across a population of elevated severity,” said Carl J. St. Bernard, Chief Executive Officer of Jupiter Endovascular.